Skip to search formSkip to main contentSkip to account menu

Targeted Accrual

Known as: Protocol Targeted Accrual, Study Targeted Accrual, Study Target Accrual 
The final sample size that must be attained according to the study protocol.
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial).
507 Background: This is a randomized phase II trial of preoperative taxane-anthracycline in combination with trastuzumab… 
2010
2010
Complete response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin's lymphoma.
8036 Background: The optimal treatment for newly diagnosed indolent non-Hodgkins lymphoma (NHL) has not been determined. While… 
2010
2010
FOLFOXIRI plus bevacizumab (BV) versus FOLFIRI plus BV as first-line treatment of metastatic colorectal cancer (MCRC): Preliminary safety results of the phase III randomized TRIBE study by the Gruppo…
3543 Background: The combination of BV with cytotoxic drugs is an efficacious strategy in the treatment of mCRC. The triple drug… 
2008
2008
Sunitinib in non-clear cell renal cell carcinoma (ncc-RCC): A phase II study
5112 Background: Sunitinib has been shown to produce high response rates (RR) with improved progression-free survival (PFS) in… 
2006
2006
The triplet combination of irinotecan, oxaliplatin and 5FU/LV (FOLFOXIRI) vs the doublet of irinotecan and 5FU/LV (FOLFIRI) as first-line treatment of metastatic colorectal cancer (MCRC): Results of…
3513 Background: We demonstrated interesting activity and manageable toxicities for the FOLFOXIRI regimen in phase I-II studies… 
2006
2006
A prospective randomized phase III, double-blind, placebo-controlled study of thalidomide in extended-disease (ED) SCLC patients after response to chemotherapy (CT): An intergroup study FNCLCC Cleo04…
7057 Background: This study aimed at determining whether or not thalidomide prolongs survival of patients (pts) suffering from… 
2006
2006
A phase II study of a weekly schedule of BMS-247550 for patients with hormone-refractory prostate cancer: A trial of the Eastern Cooperative Oncology Group (E3803).
4618 Background: BMS-247550 (ixabepilone) is an epothilone B analogue with activity in taxane-resistent cancer cell lines… 
2004
2004
Dacarbacine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) as first-line treatment of patients with metastatic melanoma: Results of a prospective-randomized phase III…
7508 Background: Progress in the treatment of patients with metastatic melanoma has been very limited over the last two decades… 
Review
2002
Review
2002
The emerging role of antifolates in the treatment of malignant pleural mesothelioma.
Clinicians have long regarded malignant pleural mesothelioma as a chemoresistant neoplasm and as a result no standard… 
2001
2001
Randomized controlled trial of ovarian function suppression plus tamoxifen versus the same endocrine therapy plus chemotherapy: is chemotherapy necessary for premenopausal women with node-positive…
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)